Q3 2025 Personalis Inc Earnings Call Transcript

Nov 4, 2025 / 10:00 PM GMT

Release Date Price: $8.73 (-3.00%)

Transcript 10-Q8-K

Key Points

Positve

Personalis Inc (PSNL) reported a significant increase in clinical test volumes, with a 26% sequential growth and a 364% year-over-year growth.
The company has over 700 physicians ordering their Next Personal test, indicating strong clinical adoption.
Personalis Inc (PSNL) achieved its primary volume target for the year ahead of schedule, demonstrating effective execution of its strategy.
The company has a strong cash position with $150.5 million in cash and short-term investments and no significant debt.
Personalis Inc (PSNL) has signed two major prospective clinical trials with biopharma customers, indicating strong demand for their MRD technology.

Negative

Total company revenue for the third quarter was $14.5 million, representing a 44% decrease compared to the same period of the prior year.
Gross margin decreased significantly to 13.2% from 34% in the prior year, primarily due to lower revenue volume and increased clinical test costs.
The company experienced logistical delays impacting the timing of samples for several large projects, increasing variability in Q4 biopharma revenue.
Personalis Inc (PSNL) had to adjust its full-year revenue guidance downward due to the uneven biopharma spending environment and logistical challenges.
Net loss for the third quarter was $21.7 million, although this was an improvement from the $39.1 million loss in the same period of the prior year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PSNL.OQ - Personalis Inc
Q3 2025 Personalis Inc Earnings Call
Nov 04, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Mm.

Mm.

.

Oh.

.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Personales's 3rd quarter 2025 earnings conference.

All participants will be in listen-only mode.

A question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please key in star and then 0 on a telephone keypad.

Please note that this event is being recorded.

I'll now hand you over to Caroline Corner of Investor Relations. Please go ahead

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.